Abstract
Six children (aged 3 years 11 months to 15 years 9 months) with end-stage renal failure and anaemia (mean haemoglobin 7.1 g/dl, range 6.3–7.7 g/dl) on thrice-weekly haemodialysis were treated with recombinant human erythropoietin (rHuEPO), given as an intravenous bolus in an escalating dose regime after dialysis. All responded with an increase in reticulocyte count and haemoglobin concentration in a mean time of 11 weeks (range 9–13 weeks) and at a dose of 100 or 150 units/kg thrice weekly. The dose of rHuEPO was then adjusted to maintain the haemoglobin concentration within the lower half of the normal range for the child's age and sex. The mean haemoglobin after 12 weeks treatment was 10.9 g/dl (range 8.5–12.1 g/dl) and after 24 weeks, 10.5 g/dl (range 7.9–13.3 g/dl). Four chidlren had no further need for blood transfusion and are thus no longer at risk of blood-borne infection, iron overload and sensitisation to HLA histocompatibility antigens. Serum ferritin fell in the three patients with evidence of iron overload; the three with low or normal iron stores at the onset of treatment maintained erythropoiesis with oral iron supplementation. HLA antibodies decreased in all patients. The only serious complication encountered was thrombosis of vascular access in one child. No child became seriously hypertensive or developed cerebral symptoms. The benefits of rHuEPO therapy for children with end-stage renal failure are potentially considerable and with careful monitoring, the risks low.
Similar content being viewed by others
References
Eschbach JW, Adamson JW (1985) Anemia of end-stage renal disease (ESRD). Kidney Int 28:1–5
Adamson JW, Eschbach JW, Finch CA (1968) The kidney and erythropoiesis. Am J Med 44:725–733
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet II:1175–1178
Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anaemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 316:73–78
Donckerwolke RA, Chantler C, Broyer M, Brunner FP, Brynger H, Jacobs C, Kramer P, Selwood NH, Wing AJ (1980) Combined report on regular dialysis and transplantation of children in Europe, 1979. Proc Eur Dial Transplant Assoc 17:87–115
Thick MG, Verbi V, Kennedy L, Welsh KI (1984) Sensitisation following kidney graft failure and blood transfusion. Transplantation 37:525–526
Diem K, Lentner C (eds) (1970) Documenta geigy scientific tables, 7th edn. Geigy Pharmaceutical Company Ltd., Manchester p 617
Blumenthal S, Epps RP, Heavenrich R, Lauer RM, Liberman E, Mirkin B, Mitchell SC, Naito VB, O'Hare D, McFate Smith T, Tarazi RC, Upson D (1977) Report of the task force on blood pressure control in children. Pediatrics 59: 797–820
Cumming GR, Everatt D, Hastman L (1978) Bruce treadmill test in children: normal values in a clinic population. Am J Cardiol 41: 69–75
Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimuzi T, Miyake T (1985) Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806–810
Lin F-K, Suggs S, Lin C-H, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai P-H, Goldwasser E (1985) Cloning and expression of the human erythro-poietin gene. Proc Natl Acad Sci USA 82:7580–7584
Eschbach JW, Adamson JW (1988) Recombinant human erythro-poietin: implications for nephrology. Am J Kidney Dis XI:203–209
Hakim RM, Stivelman JC, Schulman G, Fosburg M, Wolfe L, Imber MJ, Lazarus JM (1987) Iron overload and mobilization in long-term hemodialysis patients. Am J Kidney Dis X:293–299
Burghard R, Leititis J, Pallacks R, Scigalla P, Brandis M (1988) Treatment of a seven-year-old child with end-stage renal disease and hemosiderosis by recombinant human erythropoietin. Contrib Nephrol 66:139–148
Latta K, Offner G, Hoyer PF, Brodehl J (1988) Reduction of cytotoxic antibodies after continuous ambulatory peritoneal dialysis in highly sensitised patients. Lancet II:847–848
Brunner FP, Broyer B, Brynger H, Challah S, Fassbinder W, Oulès R, Rizzoni G, Selwood NH, Wing AJ (1985) Combined report on regular dialysis and transplantation in Europe, XV, 1984. Proc Eur Dial Transplant Assoc Eur Ren Assoc 22:5–53
Rigden SPA, Bewick M, Cahn AP, Chantler C, Van Dam M, Haycock GB, Koffman G, Taylor JO'M, Welsh KI (1987) Transplantation in the highly presensitised patient. In: Murakami K, Kitagawa T, Yabuta K, Sakai T (eds) Recent advances in paediatric nephrology. Elsevier, Amsterdam, pp 619–642
Ulmer HE, Greiner H, Schüler HW, Schärer K (1978) Cardiovascular impairment and physical working capacity in children with chronic renal failure. Acta Paediatr Scand 67:43–48
Raine AEG (1988) Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet I:97–100
Neff MS, Kim KE, Persoff M, Onesti G, Swartz C (1971) Hemodynamics of uremic anemia. Circulation 43:876–883
Remuzzi G (1988) Bleeding in renal failure. Lancet I:1205–1208
Moia M, Mannucci PM, Vizzotto L, Casati S, Cattaneo M, Ponticelli C (1987) Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet II: 1227–1229
Bommer J, Alexion C, Müller-Bühl V, Eifert J, Ritz E (1987) Recombinant human erythropoietin therapy in haemodialysis patients—dose determination and clinical experience. Nephrol Dial Transplant 2:238–242
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rigden, S.P.A., Montini, G., Morris, M. et al. Recombinant human erythropoietin therapy in children maintained by haemodialysis. Pediatr Nephrol 4, 618–622 (1990). https://doi.org/10.1007/BF00858637
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00858637